Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02565069
Other study ID # FIND-EU - CF163
Secondary ID
Status Completed
Phase Phase 4
First received September 29, 2015
Last updated April 3, 2018
Start date July 1, 2015
Est. completion date January 24, 2018

Study information

Verified date April 2018
Source Biosense Webster, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this trial is to demonstrate that the utilization of CartoFinder™ 4D Local Activation Time (LAT) Algorithm may help identify and improve the outcome for the treatment of complex arrhythmias.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date January 24, 2018
Est. primary completion date January 24, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age = 18 years.

2. Signed the Patient Informed Consent Form (ICF)

3. Scheduled to undergo a clinically-indicated catheter ablation procedure for treatment of

- Persistent atrial fibrillation (defined as continuous atrial fibrillation that is sustained beyond seven consecutive days).

- Drug-resistant Atrial Fibrillation. (failed 1 or more class I or III antiarrhythmic drugs) and demonstrating Persistent AF (requiring drugs or electrical shock to terminate)

- Persistent AF despite prior conventional ablation.

4. Previous procedure permitted but limited to single Pulmonary Vein Isolation (PVI).

5. In AF at the time of the Pre-CartoFinder Map (spontaneous or induced)

6. Able and willing to comply with all pre-, post-, and follow-up testing and requirements.

Exclusion Criteria:

1. Paroxysmal Atrial Fibrillation

2. Continuous AF > 12 months (1-Year) (Longstanding Persistent AF)

3. Cardioversion refractory (The inability to restore sinus rhythm for 30 secs or longer following electrical cardioversion. If a patient does not have documented evidence of being successfully cardioverted (Normal Sinus Rhythm (NSR) > 30 secs), the patient must be cardioverted prior to the ablation procedure. Failure to cardiovert based on the above criteria is considered a screen failure.

4. A complex arrhythmia secondary to a reversible or non-cardiac cause. For example: a complex arrhythmia secondary to electrolyte imbalance or thyroid disease.

5. Left atrial size >55 mm (echocardiography, parasternal long axis view).

6. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.

7. Structural atrial disease such as a prior history of atriotomy from prior atrial surgery, presence of an atrial septal defect, and/or presence of an atrial septal closure patch.

8. History of or current blood clotting or bleeding abnormalities, contraindication to systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin inhibitor), significant pulmonary disease, cardiac surgeries, unstable angina, uncontrolled heart failure, acute illness or systemic infection, or any other disease or malfunction that would preclude treatment in the opinion of the investigator.

9. Enrollment in an experimental study evaluating another device or drug under investigation.

10. Prosthetic valve

11. Presence of intramural thrombus, tumor or other abnormality / condition that precludes vascular access, catheter introduction or manipulation.

12. Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the trial.

13. Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CartoFinder™ Device with CARTO® 3 System V5 Navigation
Ablation treatment

Locations

Country Name City State
Belgium Onze-Lieve-Vrouwziekenhuis (OLV) Hospital Aalst Moorselbaan
Belgium Algemeen Ziekenhuis (AZ) Sint Jan Brugge Ruddershove Brugge
Belgium Universitair Ziekenhuis A ntwerpen (UZA) Wilrijkstraat Edegem
Czechia Ceské Budejovice Hospital Ceské Budejovice Nemcové

Sponsors (1)

Lead Sponsor Collaborator
Biosense Webster, Inc.

Countries where clinical trial is conducted

Belgium,  Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identify rate of slowing for the overall mean atrial fibrillation rate Identify rate of slowing for the overall mean atrial fibrillation rate that can be achieved by using CARTOFINDER™ 4D LAT Algorithm Day 0 (procedure date)
Primary Evaluate Freedom from procedure-related primary adverse events Evaluate Freedom from procedure-related primary adverse events at 7 days post-procedure 7 days
Secondary Evaluate procedural results Proportion of subjects with focal impulses / Repetitive Activation Pattern (RAP)s and number of areas and locations of focal impulses / RAPs Day 0 (procedure date)
Secondary Evaluate procedural results Proportion of subjects with Normal Sinus Rhythm (NSR) after CF guided ablation Day 0 (procedure date)
Secondary Evaluate procedural results Proportion of subjects with AF organization after CF guided ablation Day 0 (procedure date)
Secondary Evaluate procedural results Proportion of subjects with acute procedural success, i.e. subjects with spontaneous return to NSR or AF organization after CF guided ablation Day 0 (procedure date)
Secondary Evaluate freedom from documented recurrence of atrial fibrillation Evaluate freedom from documented recurrence of atrial fibrillation at 6 and 12 months post-procedure 6 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03289429 - Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery Phase 4
Unknown status NCT01834872 - Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation Phase 4
Withdrawn NCT01026961 - Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers Phase 1/Phase 2
Not yet recruiting NCT05994755 - Association Between Cardiac ARRHYTHMIAs and Glycemic Variability in Patient With Type 2 Diabetes Monitored Through FREEstyle Libre and Bluetooth Technology.
Not yet recruiting NCT06039176 - Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Completed NCT02598258 - Hemodynamic Effects of Dry Sauna Followed by Cold Water Immersion in Healthy Subjects N/A
Withdrawn NCT02575534 - Acute Mechanical Response to Anti-arrhythmic Drug Therapy N/A
Withdrawn NCT00580255 - Comparison Study of BNP and Thoracic Impedance Measurements on Arrhythmias N/A
Completed NCT00751738 - Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs) Phase 3
Completed NCT02629445 - HIPACE High Frequency Low Energy Pacing to Terminate Fast Ventricular Arrythmias N/A
Recruiting NCT04563091 - Potassium Kinetic During and After Hemodialysis and Potassium Profiling to Prevent Arrhythmias N/A
Completed NCT00589849 - T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy N/A
Active, not recruiting NCT03121183 - Medico-economic Evaluation of Strategies for the Lead Extraction of Implantable Defibrillator and Pacemakers N/A
Completed NCT02110004 - Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man Phase 1
Completed NCT02045043 - Genetic Risk Assessment of Defibrillator Events N/A
Recruiting NCT01717469 - Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Phase 4
Completed NCT00919568 - Monitoring Arrhythmia Patients (IMPACT) N/A
Terminated NCT00124891 - Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia Phase 2
Withdrawn NCT01651702 - Comparison of Carto Versus Ensite 3D Electroanatomical Mapping Systems for Arrhythmias Ablations N/A
Completed NCT03110146 - EnSite Precision 2.1 Feasibility Study